Dyadic International’s (DYAI) Buy Rating Reiterated at HC Wainwright

Dyadic International (NASDAQ:DYAI)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $6.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 435.71% from the stock’s current price.

Dyadic International Stock Down 1.8 %

DYAI stock opened at $1.12 on Thursday. Dyadic International has a fifty-two week low of $0.93 and a fifty-two week high of $2.67. The stock has a market capitalization of $33.02 million, a price-to-earnings ratio of -4.87 and a beta of 0.72. The business’s fifty day moving average price is $1.13 and its two-hundred day moving average price is $1.42. The company has a debt-to-equity ratio of 1.72, a current ratio of 5.39 and a quick ratio of 5.39.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.06. The company had revenue of $1.96 million for the quarter, compared to analysts’ expectations of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 140.01%. During the same period last year, the firm earned ($0.06) earnings per share. On average, equities analysts anticipate that Dyadic International will post -0.28 earnings per share for the current year.

Institutional Trading of Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. boosted its stake in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 847,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the quarter. Chapin Davis Inc. owned about 2.90% of Dyadic International worth $1,254,000 at the end of the most recent reporting period. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.